Quality-of-life after radiotherapy for advanced laryngeal cancer: Results of a phase III trial of the Dutch Head and Neck Society.

Autor: Janssens GO; Department of Radiation Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands; Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands. Electronic address: g.o.r.janssens@umcutrecht.nl., Langendijk JA; Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, The Netherlands., Terhaard CH; Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands., Doornaert PA; Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands., van den Ende P; Department of Radiation Oncology (MAASTRO), Maastricht University Medical Centre, The Netherlands., de Jong MA; Department of Clinical Oncology, Leiden University Medical Centre, The Netherlands., Takes RP; Department of Oto-Rhino-Laryngology and Head & Neck Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands., Span PN; Department of Radiation Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands., Kaanders JH; Department of Radiation Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Jazyk: angličtina
Zdroj: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2016 May; Vol. 119 (2), pp. 213-20. Date of Electronic Publication: 2016 May 08.
DOI: 10.1016/j.radonc.2016.02.023
Abstrakt: Background/purpose: To report on health-related quality-of-life (HRQoL) of patients with laryngeal cancer, treated in a randomized trial comparing accelerated radiotherapy with carbogen and nicotinamide (ARCON) against accelerated radiotherapy alone (AR).
Material/methods: HRQoL was assessed using the HRQoL Questionnaire-C30 (QLQ-C30) and the Head & Neck cancer module (QLQ-H&N35) at baseline, at completion of radiotherapy and at 6, 12, and 24months post-baseline.
Results: From 269/345 patients (AR: 136/174; ARCON: 133/171) data on HRQoL were available for analysis. Moderate to severe clinical impact of the treatment was observed for nearly all items of the QLQ-C30 and QLQ-H&N35 between baseline and end-of-treatment. At 6months, scores returned to baseline level with exception of dry mouth, sticky saliva, and taste/smell. No difference between AR and ARCON was observed. At 2years from baseline, the percentage of patients reporting moderate to severe complaints of dry mouth, sticky saliva, or changes in taste/smell was 30%, 22% and 18%, respectively, while the majority of patients had no or few complaints of swallowing (79%) or speech (64%).
Conclusions: With accelerated radiotherapy, high local tumor control was obtained while maintaining good speech and swallowing function. Long-term dry mouth, sticky saliva and changes in taste/smell are limited to one quarter of patients. (ClinicalTrials.gov number, NCT00147732).
(Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: